Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?

Research output: Contribution to journalReview article

Abstract

Since over 70% of patients with non-small cell lung cancer (NSCLC) have advanced (locally advanced or metastatic) disease, the majority of NSCLC patients might benefit from chemotherapy. During the past decade, a number of new agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, irinotecan, and topotecan) have been found to be effective against lung cancer. These agents have been combined with cisplatin, carboplatin, and nonplatinum drugs to treat NSCLC. They, in general, produce median survival times of 8-10 months and 1- and 2-year survival rates of 35%-40% and 10%-15%, respectively. Based on this review, there is not a preferred combination chemotherapy regimen to treat advanced NSCLC patients. However, there are a number of different regimens from which to choose.

Original languageEnglish (US)
Pages (from-to)226-233
Number of pages8
JournalOncologist
Volume7
Issue number3
DOIs
StatePublished - Jun 27 2002

Keywords

  • Combination chemotherapy
  • Metastatic non-small cell lung cancer
  • Phase III studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Is there a preferred combination chemotherapy regimen for metastastic non-small cell lung cancer?'. Together they form a unique fingerprint.

  • Cite this